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Nucleolar-nucleoplasmic shuttling 
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damage-induced poly-ADP-
ribosylation and by nucleolar 
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Patricia Verheugd1 & Bernhard Lüscher1
Macrodomains are conserved protein folds associated with ADP-ribose binding and turnover. ADP-
ribosylation is a posttranslational modification catalyzed primarily by ARTD (aka PARP) enzymes in 
cells. ARTDs transfer either single or multiple ADP-ribose units to substrates, resulting in mono- or poly-
ADP-ribosylation. TARG1/C6orf130 is a macrodomain protein that hydrolyzes mono-ADP-ribosylation 
and interacts with poly-ADP-ribose chains. Interactome analyses revealed that TARG1 binds strongly 
to ribosomes and proteins associated with rRNA processing and ribosomal assembly factors. TARG1 
localized to transcriptionally active nucleoli, which occurred independently of ADP-ribose binding. 
TARG1 shuttled continuously between nucleoli and nucleoplasm. In response to DNA damage, which 
activates ARTD1/2 (PARP1/2) and promotes synthesis of poly-ADP-ribose chains, TARG1 re-localized to 
the nucleoplasm. This was dependent on the ability of TARG1 to bind to poly-ADP-ribose. These findings 
are consistent with the observed ability of TARG1 to competitively interact with RNA and PAR chains. 
We propose a nucleolar role of TARG1 in ribosome assembly or quality control that is stalled when 
TARG1 is re-located to sites of DNA damage.
ADP-ribosylation is a reversible post-translational modification and involves the transfer of ADP-ribose 
(ADPr) units from the cofactor NAD+ onto substrate proteins. In cells, ADP-ribosylation is catalyzed by the 
ADP-ribosyltransferase (ART) family, referred to as ART diphtheria toxin-like or ARTD enzymes (aka PARPs)1,2. 
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Mono-ADP-ribosylation (MARylation), the transfer of a single ADPr unit to substrates, is catalyzed by the 
majority of ARTD enzymes and regulates a variety of cellular processes such as cell proliferation, signaling and 
transcription3. In poly-ADP-ribosylation (PARylation) reactions, multiple ADPr moieties are transferred to a sub-
strate in an iterative manner, resulting in modification by long, sometimes branched ADPr chains. PARylation is 
catalyzed by ARTD1, 2, 5 and 6 (PARP1 and 2, Tankyrase 1 and 2, respectively). ARTD1/2-mediated PARylation 
plays important roles in cellular stress signaling pathways and auto-modification of ARTD1/2 and PARylation of 
histones and other chromatin-associated proteins occurs quickly in response to DNA damage2,4. Moreover, PAR 
chains provide binding sites for DNA repair and chromatin remodeling factors, promoting efficient repair2. These 
interactions are mediated by a number of PAR binding domains, including macrodomains. Protein PARylation 
after DNA damage is of transient nature and PAR chains are quickly degraded by PARG (poly-ADP-ribose glyco-
hydrolase), the catalytic function of which is mediated by a macrodomain5.
Macrodomains are structurally conserved protein domains of 130–190 amino acids found in eukaryotes, 
prokaryotes and viruses6,7. Macrodomains adopt a globular α/β/α-sandwich fold and possess a pocket for binding 
to ADPr or other NAD+-derived metabolites such as O-acetyl-ADPr (OA-ADPr). Macrodomains differ in their 
affinities, substrate specificities and activities, interacting specifically with either free and/or protein-bound ADPr 
or with PAR chains, or both. Some macrodomains exert hydrolytic activity towards ADP-ribosylated proteins. 
Macrodomains are therefore central to ADPr biology serving as either binding modules for ADP-ribosylated 
proteins or as hydrolases of ADP-ribosylation. PARG degrades PAR chains by hydrolyzing the glycosidic 
bond between two ribose sugars but does not cleave the linkage between the protein-proximal ADPr residue 
and the modified amino acid5. Thus, to completely reverse ADP-ribosylation, specific mono-ADPr-hydrolases 
are required. Three of the 11 human macrodomain-containing proteins known thus far, MacroD1, MacroD2 
and TARG1/C6orf130, have been characterized as mono-ADPr-specific hydrolases, reverting glutamate/
aspartate-linked MARylation6,8–11. While MacroD1 and MacroD2 are closely related at the sequence level 
(MacroD-type macrodomains), TARG1 is unique among the macrodomain-containing MAR hydrolases, as it 
is phylogenetically related to ALC-type macrodomains7. TARG1 is postulated to employ a different catalytic 
mechanism compared to the MacroD-type hydrolases9. In addition to hydrolysis of MARylation, TARG1 exerts 
OA-ADPr deacetylase activity12 and can remove whole PAR chains from PARylated ARTD19, the latter represent-
ing a unique, but rather weak activity among all so far identified MAR hydrolases9,13. In cells, TARG1 interacts 
with ARTD1 and is recruited to sites of laser-induced DNA damage dependent on PARylation9. TARG1 depletion 
from HEK293 and U2OS cells was suggested to increase senescence and sensitivity to DNA damaging agents, 
indicating a role in DNA repair9. An inactivating homozygous mutation in the TARG1-encoding OARD1 gene 
has been correlated with childhood neurodegeneration9.
Although now generally accepted as an ADPr binding module, macrodomains possess a variety of binding 
properties beyond ADPr or its directly related metabolites. At least some macrodomains interact with long neg-
atively charged polymers, which can be PAR but also poly(A)+ RNA, other single stranded (ss) RNA molecules, 
or oligo(G) nucleotides14–18. Binding of these polymers including PAR is not necessarily mediated by interaction 
with the ADPr binding pocket, but rather appears to involve interaction with positively charged patches on the 
surface of the macrodomains14.
While addressing the role of TARG1 in regulating chromatin, we noticed that the protein is predominantly 
located in nucleoli. Therefore, we characterized the TARG1 interactome. Ribosomal proteins and proteins asso-
ciated with rRNA metabolism and RNA binding were the main interaction partners. However, when ARTD1/2 
were activated in cell extracts, a strong shift in the interactome towards PARylated proteins was noticed. 
Furthermore, we observed that TARG1 shuttles continuously between nucleoli and the nucleoplasm and accu-
mulates in transcriptionally active nucleoli under steady-state conditions. Upon DNA damage rapid and reversi-
ble relocation into the nucleoplasm occurred, which was dependent on the ADPr binding ability of TARG1. The 
accumulation in nucleoli and PARylation-dependent relocation to the nucleoplasm are consistent with the ability 
of TARG1 to bind RNA and PAR in a competitive manner. In conclusion, we propose that TARG1 is a nucleolar 
ribosome biosynthesis quality control factor.
Results
Tandem-affinity purification reveals interaction of TARG1 with RNA-binding proteins. To gain 
insight into TARG1’s cellular functions, we identified the TARG1-associated cellular proteome using a tandem 
affinity purification (TAP) approach19. HEK293 cells stably and inducibly expressing TAP-tagged TARG1 or the 
TAP-tag alone were generated and TAP-containing protein complexes isolated (Fig. 1a)20. The TAP-tag consists of 
Protein A fused to a Calmodulin (CaM) binding peptide (CBP) via a Tobacco Etch Virus (TEV) protease cleavage 
site (Fig. 1a), allowing for sequential affinity purification of TAP-tag-containing complexes. Protein A is captured 
by an IgG matrix, complexes are eluted by TEV cleavage and CBP-tagged complexes are recovered by a CaM pull-
down (Fig. 1a). Co-purified proteins were analyzed by LC-MS/MS and relative enrichment of detected proteins in 
the TAP-TARG1 pulldown over the TAP-tag control was calculated by label-free quantitation (Fig. 1b and c)21,22. 
Because mechanical DNA shearing during cell lysis activates ARTD1/2 resulting in PAR formation, to which 
TARG1 can be recruited9,23, we assessed the role of PAR on the TARG1 interactome. Therefore, the experiments 
were performed with or without the ARTD1/2 inhibitor olaparib during cell lysis (Fig. 1a). Experiments without 
inhibitor were performed in three, experiments with inhibitor in two biological replicates. The individual sam-
ples were measured in technical duplicates. Without inhibitor we identified 70 TARG1 interacting proteins with 
a fold enrichment ≥2 (Fig. 1b, Supplementary Table S1, Supplementary Dataset S1). ARTD1, the only described 
interaction partner of TARG1 so far9, was highly enriched (Fig. 1c; Supplementary Table S1, Supplementary 
Dataset S1). In addition, components of protein complexes involved in base excision repair (BER; XRCC1 and 
LIG3), in non-homologous end joining (NHEJ; PRKDC, XRCC5 and XRCC6) and the FACT (facilitates chro-
matin transcription) complex subunits SSRP1 and SUPT16H were associated with TARG1. All of these factors 
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Figure 1. Tandem affinity purification of TARG1-containing protein complexes suggests functions of TARG1 in 
RNA biology. (a) Left panel: HEK293 Flp-In™ T-REx™ cells expressing TAP-TARG1 or the TAP-tag alone after 
doxycycline induction were lysed in the presence or absence of olaparib to inhibit ARTD1/2 activation during cell 
lysis. TAP-tag containing complexes were purified in two sequential affinity purification steps. Co-purified proteins 
were analyzed by LC-MS/MS and relative enrichment of TAP-TARG1 over TAP-tag control was determined by label-
free quantitation (LFQ). Upper right panel: Domain structure of TAP-TARG1 and TAP constructs. Lower right panel: 
Fractions of the input lysate, the IgG and the CaM pulldown were analyzed for TARG1 by Western blot using mAb 
3A5 (for characterization of TARG1 antibodies see Supplementary Fig. S3). (b) Venn diagrams depicting the overlap 
between proteins associated with TARG1 in proteomics screens conducted in the absence (three biological replicates, 
p ≤ 0.01) or presence (two biological replicates, p ≤ 0.01) of olaparib in the lysis buffer with a fold enrichment of ≥2 
(upper diagram) or ≥10 (lower diagram) over TAP control. (c) Fold enrichment of all proteins identified as TARG1 
interacting proteins (p ≤ 0.01, ≥2-fold enrichment over TAP control) both in the absence and presence of olaparib. 
Only a fraction of grouped bars is specified with the corresponding protein names on the x-axis for clarity reasons. 
For details on the identified proteins see Supplementary Table S1, Supplementary Datasets S1 and S2. (d) HEK293 
cells were transfected with plasmids encoding for FLAG-TARG1 wildtype (WT) or ADPr binding-deficient FLAG-
TARG1-G123E (GE). Presence of SSRP1, XRCC1 and CHD1L in FLAG immunoprecipitates (IP) and whole cell 
lysates (WCL) was analyzed by Western blotting. (e) HEK293 cells transiently expressing FLAG-TARG1 were lysed 
in TAP lysis buffer ±10 µM olaparib. Presence of ARTD1, XRCC1, CHD1L, KU80 and TARG1 after IP of FLAG-
TARG1 was analyzed by Western blotting. (f) HEK293T cells transiently expressing FLAG-TARG1 were lysed in 
the presence of 10 µM olaparib. Presence of ARTD1, NCL, RPL7A and USP10 after IP against FLAG-TARG1 was 
analyzed by Western blotting. CHD1L was detected to control for inhibition of lysis-induced PARylation. (d–f) Full-
length blots are presented in Supplementary Fig. S8.
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have been consistently found as proteins that are PARylated in response to DNA damage or are recruited to sites 
of DNA damage via PAR binding domains23,24.
To assess whether these interactions depend on PARylation, we generated different ADPr binding-deficient 
TARG1 mutants. Based on in silico mutational analyses of the ADPr binding pocket in TARG1, we mutated 
three residues located in the ADPr binding pocket, G43, I44 and G123, to glutamate (Supplementary Fig. S1a–c, 
Supplementary Table S2). Mutation of G123 was previously shown to block ADPr binding9. Impact of the muta-
tions on folding and ADPr binding was assessed in fluorescence-based thermal shift assays25. His-TARG1-G43E 
and -I44E were less, His-TARG1-G123E more stable than the wildtype protein (Supplementary Fig. S1d). While 
His-TARG1 was stabilized by ADPr, the mutants were not, indicative of loss of ADPr binding (Supplementary 
Fig. S1d). Moreover, all three mutants were catalytically inactive towards auto-modified ARTD10 (Supplementary 
Fig. S1e). Consistent with these findings and unlike the wildtype protein, TARG1-G123E did not interact with 
repair proteins in co-immunoprecipitation (co-IP) experiments (Fig. 1d).
In the presence of olaparib a strong shift was observed in TARG1 co-purified proteins (Fig. 1b). The +olapa-
rib dataset contained 192 proteins with a ≥2-fold enrichment with an overlap of 32 proteins to the –olaparib 
dataset (Fig. 1b). The lost proteins with olaparib included those being either substrates of or recruited by DNA 
damage-induced PARylation (Fig. 1c and e). Increasing the stringency to a threshold of ≥10 resulted in an overlap 
of only one protein, RFC2 (replication factor C subunit 2), in addition to TARG1 itself (Fig. 1b). In the presence of 
olaparib, we identified almost all proteins of the small and large ribosomal subunits and proteins involved in ribo-
some biogenesis, RNA processing and translation such as nucleolin (NCL), hnRNPs and DDX proteins (Fig. 1c, 
Supplementary Table S1, Supplementary Dataset S2). Among the ARTD family members, association of TARG1 
with ARTD1 and the catalytically inactive ARTD13 was observed. However, while ARTD1 was highly enriched in 
the absence of olaparib treatment (385-fold), it was only weakly interacting (2.6-fold) with TARG1 with ARTD1/2 
inhibition (Fig. 1c, Supplementary Table S1, Supplementary Dataset S2). Independent co-IP experiments using 
FLAG-tagged TARG1 from cell lysates in the presence of olaparib confirmed binding to ARTD1, NCL, RPL7A, 
and USP10 (Fig. 1f). CHD1L was not co-IPed, indicating that lysis-induced PAR formation was very low or did 
not occur in these experiments (Fig. 1f). We were not able to IP endogenous TARG1 under co-IP conditions with 
any of our monoclonal and polyclonal antibodies despite their reactivity with endogenous TARG1 on Western 
blots and in high stringency IP buffers (for control Western blots see below). A possible explanation is that the 
epitopes of this small protein are covered by interacting factors under low stringency conditions.
In summary, we observed a shift of proteins co-purifying with TARG1, depending on the addition of the 
PARP inhibitor olaparib to the lysis buffer (Fig. 1b and c). Gene ontology (GO) analyses revealed distinct biolog-
ical and molecular functions associated with these proteins (Fig. 1c, Supplementary Table S3). Under –olaparib 
conditions, chromatin-related processes such as DNA repair, chromatin organization and DNA binding were 
overrepresented, while with inhibition of ARTD1/2 RNA-related processes such as translation, rRNA metabolic 
process and RNA binding prevailed (Fig. 1c, Supplementary Table S3).
TARG1 does not affect cell proliferation or translation of HeLa cells. To evaluate a potential role 
of TARG1 in cell proliferation and translation, we established HeLa OARD1−/− cells using the CRISPR-nCas9 
system26. We designed four gRNAs targeting nCas9 to loci in introns 2 and 5 of the OARD1 gene, resulting in the 
deletion of a fragment comprising exons 3–5 (Supplementary Fig. S2a). We identified two clones with the desired 
deletion in the OARD1 gene by genomic PCR (Supplementary Fig. S2b). No residual TARG1 protein was detected 
in lysates of the HeLa knock-out clones by Western blot analyses using both mAbs and pAbs (Fig. 2a; antibodies 
are described in Supplementary Fig. S3).
We measured cell proliferation of the two HeLa OARD1−/− clones by counting living cells over 7 days. While 
clone 12 HeLa OARD1−/− cells proliferated as fast as wildtype cells, the proliferation rate of cells generated from 
clone 3 was reduced by half (Fig. 2b). The reduction of cell proliferation observed for HeLa OARD1−/− clone 3 was 
not caused by the loss of TARG1, as complementation with a lentiviral vector expressing HA-TARG1 wildtype 
or HA-TARG1-G43E did not affect proliferation (Fig. 2c and d). Similarly, substantial overexpression of TARG1 
or TARG1-G123E or shRNA-dependent knockdown of OARD1 in HeLa Flp-In™ T-REx™ cells did neither affect 
cell proliferation nor sensitivity to DNA damage-inducing agents (Supplementary Figs S4 and S5). In summary, 
although it had been observed previously that TARG1 has growth promoting functions in HEK293/293T, NIH3T3, 
HSC58 and HSC60 cells9,27, our findings suggest that TARG1 does not affect cell proliferation in HeLa cells.
Because of the strong enrichment of ribosomal proteins in the TARG1-associated proteome, we next 
addressed whether TARG1 plays a role in translation. Cells lacking TARG1 or expressing a catalytically inactive 
mutant did not show obvious defects in protein biosynthesis (Supplementary Fig. S6), in agreement with the lack 
of effects on cell proliferation in HeLa cells.
EGFP-TARG1 accumulates in transcriptionally active nucleoli independent of ADP-ribose binding. 
EGFP-TARG1 was reported to be predominantly nuclear9, and our proteomics data set contained a high 
number of nuclear and in particular nucleolar proteins, also reflected by GO analyses for cellular component 
(Supplementary Table S3). Therefore, we analyzed the sub-cellular localization of TARG1 in greater detail. 
EGFP-TARG1 expressed in U2OS cells accumulated in nucleoli in living cells, while EGFP alone was excluded 
from nucleoli (Fig. 3a). mCherry-tagged Histone H2B was used to define the nucleoplasm28.
TARG1 is recruited to PAR chains during DNA damage and PAR and ARTD1/2 are found enriched in nucle-
oli in non-stressed cells2,9,29–33. Therefore, we asked whether nucleolar accumulation of TARG1 is dependent on 
its ability to interact with ADPr. All three ADPr binding-deficient TARG1 mutants accumulated in nucleoli in 
U2OS cells (Fig. 3b, Supplementary Fig. S7). Furthermore, treatment of U2OS cells with olaparib did not change 
the sub-cellular distribution of EGFP-TARG1 (see also below), together indicating that nucleolar localization of 
TARG1 is not dependent on nucleolar PAR.
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The nucleolus is involved in the cellular stress response, in line with rapid changes of the nucleolar proteome 
upon stress34. Inhibition of rRNA transcription by actinomycin D results in nucleolar disruption and release of 
nucleolar proteins, including ribosomal proteins, into the nucleoplasm34. Actinomycin D treatment, which at low 
concentration inhibits primarily RNA polymerase I, abrogated nucleolar accumulation of EGFP-TARG1 (Fig. 3c). 
The same was observed for EGFP-TARG1-G123E, indicating that loss of nucleolar accumulation of TARG1 upon 
actinomycin D treatment was PARylation-independent (Fig. 3c). Thus, TARG1 is recruited into transcriptionally 
active nucleoli independent of ADPr binding.
EGFP-TARG1 is rapidly exchanging between the nuclear and the nucleolar compartment. The 
nucleolar compartment consists of highly dynamic protein-protein and protein-nucleic acid interactions and 
nucleolar components typically continuously exchange with the surrounding nucleoplasm, important for quickly 
responding to cellular stress35–38. Therefore, we assessed the exchange of EGFP-TARG1 between the nucleop-
lasm and nucleoli using fluorescence loss in photo-bleaching (FLIP) experiments in U2OS cells. Several regions 
of interest (ROIs) were defined, one for bleaching and one for measuring were placed in the nucleoplasm, one 
in a nucleolus, one in the cytoplasm, and a control ROI in a neighboring cell to account for changes during 
the measurements. After acquisition of five control images, one nucleoplasmic ROI was exposed to repetitive 
photo-bleaching. After each bleach pulse imaging scans were performed and mean EGFP intensities were deter-
mined in all ROIs. EGFP fluorescence intensities in control regions remained constant (Fig. 4b–d), indicating 
that the effect of bleaching during image acquisition between the bleach pulses was negligible. EGFP intensities in 
each ROI were normalized to the mean EGFP intensity in each ROI before bleaching (Fig. 4b–d).
Nucleoplasmic bleaching in EGFP-TARG1 expressing cells resulted in depletion of nucleoplasmic EGFP flu-
orescence to ∼20% within 60 s (Fig. 4a and b, upper panel), suggesting a high mobility of EGFP-TARG1 within 
the nucleoplasm. Normalized nucleolar EGFP fluorescence decreased together with nucleoplasmic EGFP fluo-
rescence, indicating that EGFP-TARG1 exchanged rapidly between nucleoli and the nucleoplasm (Fig. 4b, upper 
panel). In contrast, EGFP fluorescence intensities in the cytoplasm decreased only slightly during 1 min of nuclear 
photo-bleaching (Fig. 4b, upper panel). As bleaching of a nuclear region can be accompanied by bleaching of 
cytoplasmic EGFP fusion proteins above and below the nucleus, a reciprocal experiment was performed, in which 
cytoplasmic EGFP was bleached. No marked decrease in nuclear/nucleolar EGFP intensity was observed (Fig. 4d, 
upper panel), altogether indicating that within 1 min no substantial nucleo-cytoplasmic EGFP-TARG1 shuttling 
occurred.
Figure 2. OARD1 knock-out does not affect cell proliferation of HeLa cells. (a) TARG1 expression was analyzed 
in whole cell lysates of HeLa cells (WT) and the HeLa OARD1−/− clones 3 and 12 by Western blotting using the 
TARG1-specific monoclonal antibody 3A5. α-Tubulin was detected as loading control. (b) Cell proliferation 
of HeLa cells and HeLa OARD1−/− clones 3 and 12 was measured by counting living cells over 7 days. (c) HeLa 
OARD1−/− (cl. 3) cells were stably transduced using a lentiviral vector allowing for doxycycline-inducible re-
expression of HA-TARG1 or HA-TARG1-G43E. TARG1 protein expression was analyzed in HeLa OARD1−/− 
HA-TARG1 wildtype or -G43E cells that were treated with 100 ng/ml doxycycline or were left untreated for 
48 h by Western blotting. α-Tubulin levels were detected as a loading control. (d) Cell proliferation of HeLa 
OARD1−/− HA-TARG1 or HA-TARG1-G43E cells, which were treated with 100 ng/ml doxycycline every 
48–72 h or were left untreated (±Dox), was measured over 7 days by counting living cells. (a and c) Full-length 
blots are presented in Supplementary Fig. S8.
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In U2OS cells expressing EGFP alone, nucleoplasmic EGFP fluorescence was depleted to ∼19% within 60 s, 
which is comparable to what was observed for EGFP-TARG1 (Fig. 4a and b, bottom panel). However, in contrast 
to EGFP-TARG1, a clear nucleo-cytoplasmic exchange of EGFP was observed during this time frame (Fig. 4b, 
bottom panel and Fig. 4d, bottom panel). Thus, EGFP but not EGFP-TARG1 exchanged rapidly between the 
cytosol and the nucleus.
We noticed that EGFP-TARG1 accumulated, albeit weakly, in the bleach ROI post-bleaching but not 
in a second ROI in the same nucleus (Fig. 4c, upper panel). Because EGFP-TARG1 is recruited to sites of 
DNA damage9 and photo-bleaching of fluorophores can be accompanied by the production of reactive oxy-
gen species39, we addressed whether PARylation was important for this effect. We performed FLIP exper-
iments with EGFP-TARG1-G123E, which is ADPr binding-deficient and is not recruited to DNA damage 
sites9. In EGFP-TARG1-G123E expressing cells, no accumulation of signal in the bleach ROI was observed 
(Fig. 4c, middle panel), indicating that EGFP-TARG1 is indeed to some extent recruited into the bleached 
region by ADP-ribosylation. However, EGFP-TARG1-G123E displayed an overall nuclear mobility and 
nucleoplasmic-nucleolar exchange similar to EGFP-TARG1 (Fig. 4a and b, middle panel). Thus, the influence of 
photo-bleaching-induced PARylation in the bleach ROI is negligible in our experiments.
Modulation of nucleolar TARG1 localization by H2O2-induced DNA damage stress. Next we 
asked whether modulation of nuclear PAR levels would affect the subnuclear localization of TARG1. Hydrogen 
Figure 3. EGFP-TARG1 localizes to transcriptionally active nucleoli independent of ADP-ribosylation. (a) Live 
cell imaging of U2OS cells transiently expressing EGFP-TARG1 or EGFP together with mCherry-H2B. Intensity 
profiles for EGFP and mCherry fluorescence signals are displayed that were measured along the arrows depicted 
in the merge pictures. DIC: differential interference contrast. (b) Live cell imaging of U2OS cells transiently 
expressing EGFP-TARG1 wildtype (WT), G43E, I44E or G123E together with mCherry-H2B. For intensity 
profiles, see Supplementary Figures S7. (c) U2OS cells transiently expressing EGFP-TARG1 or EGFP-TARG1-
G123E together with mCherry-H2B were treated with 10 ng/ml actinomycin D (ActD) or DMSO for 90 min. 
Subcellular localization of EGFP-TARG1 (wildtype or G123E) was analyzed by confocal microscopy in living 
cells.
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peroxide (H2O2), commonly used to induce oxidative DNA damage, activates ARTD1 and results in PARylation of 
ARTD1 and chromatin-associated proteins. PAR levels peak within 10–15 min after treatment and are degraded 
quickly thereafter by PARG40. In response to H2O2 treatment, EGFP-TARG1 was rapidly lost from nucleoli, 
but did not affect the localization of EGFP-TARG1-G123E (Fig. 5a and b). Olaparib prevented H2O2-induced 
re-location of TARG1, in agreement with a PARylation-dependent accumulation of EGFP-TARG1 in the nucleo-
plasm (Fig. 5c and d).
TARG1 interacts with RNA. Localization of proteins in nucleoli is often mediated by interaction with 
nucleolar RNA or by binding to nucleolar hub proteins such as NCL or nucleophosmin35. Therefore, we asked 
whether TARG1 has RNA binding activity. In an RNA electrophoretic mobility shift assay (EMSA) His-tagged 
TARG1 bound dose-dependently to 32P-labeled ssRNA Pentaprobes (Fig. 6a and b)41. The Pentaprobe plasmid 
library encodes six overlapping double stranded 100 bp long oligonucleotides that in total contain every possible 
Figure 4. EGFP-TARG1 rapidly shuttles between the nucleoplasmic and the nucleolar compartment. (a) 
Fluorescence loss in photo-bleaching (FLIP) experiments in U2OS cells transiently expressing EGFP-TARG1, 
EGFP-TARG1-G123E or EGFP. mCherry-H2B was co-expressed to define the nucleoplasm (not shown). 
Representative images are shown. (b–d) EGFP fluorescence intensities of EGFP-TARG1 (upper panels), EGFP-
TARG1-G123E (middle panels) and EGFP (lower panels) were measured in each ROI during photo-bleaching 
of nucleoplasmic EGFP (b), after total photo-bleaching of nucleoplasmic EGFP (c) or during photo-bleaching 
of cytoplasmic EGFP (d). Fluorescence intensities were normalized to the mean EGFP fluorescence intensity in 
the same ROI before bleaching and are expressed as mean ± SD of 7–12 cells as indicated.
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5 bp sequence motif, from which 12 different ssRNA molecules can be in vitro transcribed (forward and reverse)41. 
RNA binding activity of GST-ALY served as positive control (Fig. 6a and b)42,43, while GST alone did not bind 
(Fig. 6a and b). The specificity of the TARG1-RNA complex was documented by the induction of a supershift with 
a TARG1-specific antibody (Fig. 6c). TARG1 interacted equally well with several different Pentaprobe constructs 
(Fig. 6b and d), indicating that TARG1 binding to RNA is likely independent of a specific sequence. Unlabeled 
RNA isolated from cultured cells competed with TARG1 binding to the Pentaprobes (Fig. 6d).
To determine whether binding of RNA by TARG1 involves interactions with the ADPr binding site, we ana-
lyzed RNA binding by His-TARG1-G123E and -G43E (Fig. 6a). Both mutants bound to RNA in the same con-
centration range as His-TARG1 (Fig. 6b). Similarly, ADPr did not prevent RNA binding by TARG1 (Fig. 6g), 
Figure 5. Nucleolar accumulation of TARG1 is lost upon H2O2-treatment. (a) U2OS cells transiently expressing 
EGFP-TARG1 or EGFP-TARG1-G123E together with mCherry-H2B were or were not (ctrl) treated with 1 mM 
H2O2. Subcellular localization of EGFP-TARG1 (wildtype/G123E) before (−) and during the first 20 min after 
treatment was analyzed in living cells by confocal microscopy. A representative experiment is depicted. (b) 
Quantifications of nucleolar EGFP intensities from cells imaged during the experiment depicted in panel A are 
given. Nucleolar EGFP-intensities were measured using ImageJ, normalized to nuclear EGFP-intensities at each 
time point and to the normalized nucleolar EGFP intensity 1 min after treatment (mean ± SD of at least 3 cells). 
(c) U2OS cells transiently expressing EGFP-TARG1 wildtype together with mCherry-H2B were treated with 
DMSO or 10 µM olaparib for 2 h before treatment with 1 mM H2O2. Subcellular localization of EGFP-TARG1 
before (−) and during the first 20 min after treatment was analyzed in living cells by confocal microscopy. A 
representative experiment is depicted. (d) Quantifications of nucleolar EGFP intensities from cells imaged 
during the experiment depicted in panel c are given. Intensities were calculated as in panel b.
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indicating that the interaction with RNA is not or not exclusively based on binding in the ADPr binding pocket. 
Also, RNA did not increase thermal stability of TARG1 (Fig. 6e), as in the case of ADPr (Supplementary Fig. S1d). 
Instead, addition of increasing amounts of RNA to TARG1 reduced its thermal stability (Fig. 6e). When titrating 
Figure 6. TARG1 is an RNA binding macrodomain. (a) TARG1 wildtype, -G43E, -I44E and -G123E were 
expressed as N-terminal His6-tag fusion proteins in bacteria and purified by immobilized metal affinity 
chromatography (IMAC). ALY, fused to an N-terminal glutathione S-transferase (GST)-tag, was expressed 
in bacteria and purified by glutathione affinity chromatography. Aliquots of the eluates, together with a 
bovine serum albumin (BSA) standard, were separated on an SDS-gel and stained with Coomassie blue. (b) 
Electrophoretic mobility shift assay (EMSA) using RNA Pentaprobe oligonucleotides41. Purified 32P-labeled 
Pentaprobe 9 (32P-PP9) was incubated with the indicated amounts of purified GST, GST-ALY, His-TARG1 
wildtype (WT), -G123E or -G43E (2.5–20 pmol corresponding to 83.3–666 nM, respectively). Free RNA and 
RNA-protein complexes were separated on native 7% poly-acrylamide gels. Mobility shifts were analyzed by 
auto-radiography. (c) EMSA performed as described in panel b with 32P-PP9 and His-TARG1 (5 pmol, 0.16 µM), 
His-TARG1 in complex with a polyclonal antibody raised against TARG1 (Eurogentec) or with antibody 
alone. (d) EMSA of 32P-PP7 that was incubated with constant amounts of His-TARG1 (5 pmol, 0.16 µM) and 
increasing amounts of cellular RNA (5–150 pmol, corresponding to 0.16–5 µM, calculated per nucleotide). 
(e) Thermal shift assay of 2 µM His-TARG1 WT or -G123E together with increasing amounts of cellular RNA 
(5–100 µM, calculated per nucleotide). Melting temperatures were determined according to25 and are presented 
as ΔTM to H2O control (ctrl; mean ± SD of 3 experiments). (f) Thermal shift assay of 2 µM His-TARG1 WT or 
-G123E in the presence of constant amounts of cellular RNA (100 µM, calculated per nucleotide) together with 
increasing amounts of ADPr. Melting temperatures are expressed as ΔTM to H2O control (ctrl; mean ± SD of 3 
experiments). (g) EMSA of 32P-PP7 that was incubated with constant amounts of His-TARG1 WT or -G123E  
(5 pmol, 0.16 µM) and increasing amounts of purified PAR (0.5–10 pmol, calculated per ADPr unit, 
corresponding to 0.016–0.33 µM) or ADPr (50–200 pmol, corresponding to 1.66–6.66 µM).
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ADPr into an RNA-TARG1 mixture in the thermal shift assay, the negative thermal shift induced by RNA was 
reversed in a dose-dependent manner for TARG1, but not for TARG1-G123E (Fig. 6f).
The TARG1-associated proteome changed dramatically in response to PARylation. We reasoned that this 
drastic change could be caused by a switch from RNA to PAR binding of TARG1. We therefore tested whether 
PAR chains were able to compete with RNA for binding to TARG1. Indeed, titration of PAR into the RNA binding 
assay efficiently reversed the band shift induced by His-TARG1 but poorly by His-TARG1-G123E (Fig. 6g). These 
data, together with the inability of ADPr to compete, are in agreement with a model, in which TARG1 binds RNA 
via positively charged patches on its surface but not via its ADPr binding pocket. In contrast, PAR occupies the 
ADPr binding pocket of TARG1 and at the same time interacts very likely with the positively charged patches on 
the surface of TARG1. These findings support the notion that TARG1 has a higher affinity to PAR than to RNA.
Discussion
We have identified two different interactomes of TARG1, which are dependent on the presence or absence of PAR. 
In the absence of ARTD1/2 activation and PAR formation, the TARG1 interactome is strongly directed toward 
ribosomal proteins and RNA-binding proteins (RBPs) that function in diverse RNA-associated cellular processes. 
Furthermore, we observed that TARG1 is a nuclear protein that shuttles rapidly between the nucleoplasm and 
nucleoli. The distribution between these two compartments is regulated by PARylation, i.e. TARG1 is mainly 
nucleolar in the absence of PAR, while it accumulates in the nucleoplasm in response to PAR formation. We also 
discovered that TARG1 interacts with RNA, which together with binding to ribosomal proteins is suggested to 
control its nucleolar localization (Fig. 7).
The binding to ribosomal proteins and RBPs is consistent with a strong connection between RNA biology 
and ADP-ribosylation, which has been repeatedly found in proteomics screens for proteins associated with 
stress-induced ADP-ribosylation23,24,44–50. These screens commonly revealed that a high number of RNA pro-
cessing factors are ADP-ribosylated or are PAR binding proteins44,45. So far, it is unclear which of the identified 
proteins interact directly with TARG1. In addition to direct protein-protein binding, we assume that some of the 
interactions are mediated by the ability of TARG1 to associate with RNA (Fig. 6). This seems likely as a number 
of proteins were identified that are part of multi-protein and ribonucleoprotein complexes such as ribosomes. In 
contrast, when PARylation was not inhibited the interactome was dominated by DNA repair proteins of various 
processes, most of which have been shown to be PARylated or interacting with PAR23,24,47,51–54. This observation 
is consistent with the finding that TARG1 is recruited to sites of DNA damage in an ARTD1-dependent manner9. 
This efficient recruitment is also in agreement with the strong enrichment of ARTD1 in the TARG1 interactome 
in the absence of olaparib (Fig. 1).
Unlike the PAR-dependent recruitment of TARG1 to DNA damage sites9, its nucleolar localization and its 
shuttling between nucleolus and nucleoplasm is independent of ADPr binding. This might seem surprising, 
because ADP-ribosylation has been associated with nucleolar functions in a number of studies29,44,55–57. PAR, 
ARTD1 and ARTD2 can be found enriched in nucleoli under non-stress conditions and several nucleolar pro-
teins are ADP-ribosylated and/or interact with ARTD1, ARTD2 or PAR29,32,33,55. Interference with PAR metab-
olism in Drosophila results in mislocalization of nucleolar proteins and disintegration of nucleoli55. We did not 
observe fragmentation or other abnormalities of nucleoli in cells with OARD1 knock-out or TARG1 overexpres-
sion. In Drosophila Parp and Parg mutants, rRNA maturation defects have been observed, accompanied by a drop 
in cytoplasmic polysomes55. It was proposed that nucleolar PAR serves as a scaffold to recruit rRNA processing 
factors into nucleoli, which is required for accurate ribosome biogenesis55. PAR chains formed at DNA damage 
sites are capable of forming liquid phase structures together with proteins that contain low complexity domains58. 
Thus, PAR might also contribute to the liquid phase structure of nucleoli, which are formed around rDNA repeats 
Figure 7. Model of a dual function of TARG1 in both RNA- and PAR-regulated cellular processes. Under 
steady-state conditions, TARG1 accumulates in nucleoli but constantly shuttles between nucleoli and the 
nucleoplasm (1). Accumulation of TARG1 in nucleoli is mediated by direct interaction with ribosomal RNA 
or proteins (RP) or other nucleolar proteins (NP; 2). PARylation modulates the localization and interactome of 
TARG1. TARG1 re-locates to the nucleoplasm upon DNA damage-induced ARTD1/2-dependent PARylation 
(3). In nucleoli, TARG1 may contribute to ribosome biogenesis, e.g., by counteracting PARylation of RPs or 
controlling nucleolar PAR scaffolds. DNA damage-induced PARylation might serve to sequester TARG1 to the 
nucleoplasm to regulate PAR turnover at DNA damage sites (4). Hypothetical interactions are marked by grey 
arrows.
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in an incremental manner by multivalent interactions between rRNA transcripts and nucleolar proteins2,35,59–61. 
TARG1 inhibits ARTD1 in vitro and might be able to remove complete PAR chains from automodified ARTD19. 
It remains however unknown whether TARG1 is able to modulate PARylation levels by either of these mecha-
nisms in cells. Whether TARG1 is needed for nucleolar integrity by modulating nucleolar PARylation or by other 
means remains to be investigated.
Nucleolar localization of TARG1 could be mediated by direct interaction of TARG1 with nucleolar RNA. 
This is supported by the fact that two ADPr binding-deficient TARG1 mutants that retain RNA binding ability 
still localize to nucleoli and that TARG1 wildtype and mutants only locate to transcriptionally active nucleoli. 
Actinomycin D treatment induces broad changes in the nucleolar proteome62. Especially ribosomal proteins and 
ribosome biogenesis factors depend on the presence of rRNA for nucleolar localization and leave nucleoli upon 
RNA polymerase I inhibition34,62. Thus, in addition to interaction with rRNA, the possibility exists that the actin-
omycin D-induced loss of nucleolar accumulation of TARG1 is caused by more indirect mechanisms than the loss 
of direct interaction between TARG1 and nucleolar RNA.
We note that TARG1 was not identified to reside in nucleoli in a number of proteomics studies that assessed 
the composition of the nucleolar proteome. This suggests that the association of TARG1 with nucleoli is not suf-
ficiently stable and thus might be lost during purification of nucleoli, especially if purifications are performed in 
the absence of ARTD1/2 inhibitors62–64.
Several reasons encouraged us to address a potential RNA binding activity of TARG1. These included the 
localization of the protein to nucleoli, the interaction with ribosomes and RBPs, and the finding that several mac-
rodomains including the macrodomain of CHIKV-nsP3 and MacroD1 interact with RNA14,15. Our study provides 
an initial characterization of the RNA binding activity of TARG1. We found TARG1 to interact with different 
RNA molecules in EMSAs, indicating that the binding is independent of the RNA sequence. The competition 
experiments suggested that RNA binding does not rely on the ADPr binding pocket. PAR efficiently competed 
with RNA for binding to TARG1, but not for binding to TARG1-G123E. We conclude that PAR occupies the same 
regions in TARG1 as RNA, explaining the competitive binding mode. The requirement for an intact ADPr bind-
ing pocket for efficient competition suggests that PAR binding to this pocket is substantial. This is consistent with 
the roughly 10-fold more efficient competition of TARG1 RNA binding by PAR compared to RNA and by the 
inefficient competition by ADPr (Fig. 6). Thus, RNA binding occurs probably in the vicinity of the ADPr binding 
pocket of TARG1 and the efficient competition by PAR requires interaction in this pocket and at surface sites that 
also interact with RNA. The latter is supported by the presence of basic surface patches close to the ADPr binding 
pocket in TARG19, which could mediate unspecific interaction with the negatively charged RNA backbone and 
also stabilize interaction with PAR, as suggested earlier14,15.
RNA induced a dose-dependent reduction of the TARG1 melting temperature (Fig. 6). The decrease in TM of 
His-TARG1 upon incubation with RNA is likely to reflect the direct interaction of RNA with the protein, although 
TM decreases in the thermal shift assays have also been attributed to indirect effects65. Destabilization of TARG1 
by RNA was antagonized by ADPr. Of surprise was the high concentration of ADPr necessary for the stabilization 
effect, indicating that the affinity for ADPr is rather low. This is consistent with a Ki value of 119 µM for ADPr in 
OA-ADPr deacetylation reactions12, but less compatible with the Kd of 8.4 µM for ADPr9. Together with the ADPr 
competition in EMSAs, we conclude that ADPr and RNA are able to interact with TARG1 simultaneously.
What is the functional consequence of TARG1 binding to RNA and ribosomal proteins? How does this relate 
to the role of TARG1 during DNA damage-induced PARylation? So far, it is not clear whether TARG1 directly 
regulates ribosome biogenesis. According to our proteomics data, TARG1 interacts with a variety of ribosomal 
proteins and ribosome biogenesis factors, but evidence for a possible role of TARG1 in particular steps of ribo-
some biogenesis is missing presently. Based on the recruitment of TARG1 to sites of DNA damage and a decreased 
resistance to DNA damaging agents of TARG1 knock-down cells, TARG1 was proposed to act as a DNA damage 
response factor9, a finding that in our experimental set-up could not be reproduced (Supplementary Fig. S5). 
However, several RBPs and ribosomal proteins have been described as direct substrates of ADP-ribosylation 
during genotoxic stress44,66. Some of these ribosomal proteins are important for the interaction of the 40S and 
60S subunits66,67. It was proposed that ARTD1-dependent ADP-ribosylation of RPL24 at E106 and RPS8 at E89 
might interfere with the formation of inter-subunit bridges formed between RPL24 and RPS6 and between RPS8 
and the 28S rRNA, thereby regulating ribosome assembly66. These observations were made in a breast cancer 
cell line, but not in several other lines. Nevertheless, it offers the intriguing possibility that ADP-ribosylation of 
these proteins regulates ribosome assembly. Whether TARG1 can reverse these modifications and thereby mod-
ulate ribosome biogenesis remains to be determined. The maintenance of nucleolar PAR levels seems to promote 
nucleolus formation and ribosome biogenesis in Drosophila55. Whether this is also occurring in mammalian cells 
needs to be demonstrated. Nevertheless, the role of PARylation in nucleolar functions might be more complex 
than anticipated. PARylation might affect nucleolar functions by several mechanisms, acting either as a scaffold 
important for the recruitment of ribosome biogenesis factors and at the same time as a PTM of ribosomal pro-
teins, interfering with ribosome assembly. This might explain why the effects observed in OARD1 knock-out cells 
are rather weak. The presence of MacroD1 and/or MacroD2 might also compensate sufficiently for the lack of 
TARG1 and thus allow proliferation, at least in HeLa cells.
DNA damage-induced PARylation sequesters TARG1 in the nucleoplasm, where it may contribute to PAR 
turnover at DNA damage sites (Fig. 7). It is tempting to speculate that this sequestration may prevent TARG1 
from executing a so far unidentified nucleolar function, thereby contributing to the cellular stress response. 
The loss of TARG1 in humans correlates with a severe neurodegeneration phenotype9, which might be due to a 
chronic, suboptimal ribosome production. Thus, it will now be interesting to address the role of TARG1 in animal 
models, in which long-term consequences can be studied.
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Materials and Methods
Plasmids and oligonucleotides. The OARD1 coding sequence was amplified from human cDNA using 
Gateway (Invitrogen)-compatible primers and cloned into pDONR/Zeo (Invitrogen). GW-p-N-TAP-C6orf130 
was generated by Gateway recombination between pDONR/Zeo-C6orf130 and a Gateway-compatible pcDNA5/
FRT/TO-N-TAP vector20.
A sequence-optimized TARG1/C6orf130 fragment was amplified from pNic28-BSA4-C6orf130 (kindly 
provided by H. Schüler, Karolinska Institute, Stockholm) using Gateway-compatible primers and recombina-
tion into pDONR/Zeo. This pDONR/Zeo-C6orf130 clone was used for gateway cloning of the OARD1 cod-
ing sequence into pDEST17 (Invitrogen), pcDNA5/FRT/TO (Invitrogen), GW-pEGFP68, pcDNA3-FLAG, 
pLKO-T-REX-HA-DEST-Neo (kindly provided by F. Stegmeier, Novartis). For generation of pcDNA5/FRT/
TO-EGFP-TARG1 plasmids, the EGFP-TARG1 fragment from GW-pEGFP-TARG1 was amplified using primers 
containing BamHI restriction sites and cloned into pcDNA5/FRT/TO. Mutants were generated by site-directed 
mutagenesis. The mCherry-H2B plasmid was a kind gift from E. Ferrando-May (Bioimaging Center, University 
of Konstanz). The plasmid for bacterial expression of GST-ARTD10(818–1025) has been described20. pGEX-
4T1-ALY served as a plasmid for bacterial expression of GST-ALY. pcDNA3.1-based Pentaprobe plasmids were 
a gift from J. Mackay41.
For the generation of Flp-In™ T-REx™ cell lines with inducible expression of shRNA constructs, a modified 
pcDNA5/FRT/TO vector was constructed: The H1 promoter from pSUPER69 was modified with Tet regulator 
sequences. The fragment containing the modified H1 promoter and the shRNA cloning site was cloned into 
pcDNA5/FRT/TO, replacing the CMV/TetO2 promoter. A second BglII site in the resulting pcDNA5 vector was 
mutated. The resulting pcDNA5/FRT/TO-Super-Tet vector was digested with HindIII and BglII and ligated with 
annealed pairs of the oligonucleotides shTARG1_ORF_fwd (gatcgagagatgggcgatatatacgaatatatatcgcccatctctc) 
and shTARG1_ORF_rev (agctgagagatgggcgatatatattcgtatatatcgcccatctctc) or shCtrl_fwd (gatcagaagagtttagagg-
caatcgaaattgcctctaaactcttc) and shCtrl_rev (agctgaagagtttagaggcaatttcgattgcctctaaactcttct). shRNA sequences 
(underlined) were taken from9.
For the generation of CRISPR-Cas9(D10A) knock-out constructs oligonucleotides defining the gRNA 
sequences were annealed in pairs and cloned into a modified pX335 vector (Addgene 42335) containing a 
GFP-puromycin selection cassette70–72 and verified by sequencing: (1) forward: caccccaattacagcatgtgtaaa, reverse: 
aaactttacacatgctgtaattgg (2) foward: cacccagattggaggaaggggtg, reverse: aaacgcaccccttcctccaatctg (3) foward: 
caccgctctctgctaagcaggctg, reverse: aaaccagcctgcttagcagagagc (4) forward: caccagcaccctctgcttgaagct, reverse: 
aaacagcttcaagcagagggtgc.
Cell lines and cell culture. All cell lines were cultivated in DMEM supplemented with 10% heat-inactivated 
fetal calf serum (FCS) and 1% penicillin/streptomycin at 37 °C in 5% CO2 in a humidified atmosphere. 
Transfections were performed using calcium phosphate precipitation.
HeLa Flp-In™ T-REx™ (kindly provided by Stephen Taylor, University of Manchester) and HEK293 Flp-In™ 
T-REx™ cells (Invitrogen) were generated according to manufacturer’s instructions with the plasmids pcDNA5/
FRT/TO, pcDNA5/FRT/TO-TARG1, pcDNA5/FRT/TO-TARG1 G123E, GW-pN-TAP-C6orf130, pcDNA5/FRT/
TO-Super-Tet-shOARD1, pcDNA5/FRT/TO-Super-Tet-shCtrl and selected with hygromycin B and blasticidin S. 
HEK293 Flp-In™ T-REx™ N-TAP cells were described previously20.
HeLa OARD1−/− cell clones were generated by transfection of HeLa cells with equal amounts of four different 
pX335 plasmids encoding the four different gRNAs for 24 h, followed by selection of transfected cells with 1 µg/ml 
puromycin for 24 h. Single cell clones were picked after ∼14 days and were expanded. Genomic DNA was isolated 
from each clone using the High Pure PCR Template Preparation Kit (Roche) and used as a template in genotyping 
PCR reactions using oligonucleotides Ex4-fwd (tgggttgtgaggaaacatga) and Ex4-rev (gccatcactggactggagtt) for 
amplification of the wildtype allele and Ex1_fwd (tggttgtacagggcaatcag) and Int5-rev (ttgcaacaccctggtaagaa) for 
identification of the deletion.
HeLa OARD1−/− HA-TARG1 and HeLa OARD1−/− HA-TARG1-G43E cells were generated by lentiviral trans-
duction of HeLa OARD1−/− cells with pLKO-TREX-HA-TARG1 plasmids and were selected with G-418.
Antibodies and reagents. Polyclonal rabbit anti-TARG1 was raised against two TARG1 peptides (1) aa 
138–152 (EVFEATDIKITVYTL) and (2) aa 119–134 (RIGCGLDRLQWENVSA; Eurogentec). Monoclonal anti-
bodies were generated against His6-TARG1 (full-length, gift from I. Ahel, University of Oxford): 3A5 (rat), 31F6 
(mouse), 6F11 (rat), 28E9 (mouse) and 26E4 (mouse) (E. Kremmer, R. Feederle). Additional antibodies used 
were as follows: anti-SSRP1 (E1Y8D, Cell Signaling Technology), XRCC1 (#2735BC, Cell Signaling Technology), 
anti-CHD1L (E1I8C, Cell Signaling Technology), anti-PARP1 (1835238, Roche), anti-KU80 (C48E7, Cell 
Signaling Technology), anti-NCL (4E2, abcam), anti-RPL7a (E109, Cell Signaling Technology), anti-USP10 
(D7A5, Cell Signaling Technology), anti-α-Tubulin (B512, Sigma-Aldrich), anti-puromycin (12D10, Merck 
Millipore), peroxidase-conjugated goat anti-rabbit IgG (H + L), peroxidase-conjugated goat anti-mouse IgG 
(H + L), peroxidase-conjugated goat anti-rat IgG + IgM (H + L) (Jackson Immunoresearch). Oligonucleotides 
were purchased from Sigma-Aldrich. The following reagents were used: β-NAD+ (Sigma-Aldrich), 32P-NAD+ 
(Perkin Elmer), α-32P-UTP (Hartmann Analytic), adenosine 5′ diphosphoribose sodium-salt (Sigma-Aldrich), 
poly-ADP-ribose (4336–100–01, Trevigen), olaparib (Sellekchem), protease inhibitor cocktail P8340 
(Sigma-Aldrich), RNase inhibitor, murine (M0314, NEB), AcTEV protease (Invitrogen), glutathione agarose 
(Pierce™), TALON® metal affinity resin (Clontech), IgG Sepharose® 6 Fast Flow (GE Healthcare), Calmodulin 
Sepharose® 4B (GE Healthcare), anti-FLAG® M2 affinity gel (Sigma-Aldrich), actinomycin D (Sigma-Aldrich), 
puromycin (AppliChem), hygromycin B (Invivogen), blasticidin S (Invivogen), G-418 (Invivogen), DMSO 
(AppliChem), H2O2 (Merck KGaA), cell proliferation reagent WST-1 (Roche), bovine serum albumin (BSA; 
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AppliChem), etoposide (Biomol), doxorubicin (Sigma-Aldrich), hydroxyurea (Sigma-Aldrich), SYPRO® orange 
(ThermoFisher Scientific), doxycycline (Sigma-Aldrich).
Tandem affinity purification. Large-scale purification of TAP-TARG1-containing protein complexes was 
performed as described previously20 with a few modifications: 5 × 107 cells were trypsinized and transferred to 
spinner flasks in 250 ml non-selective cell culture medium. Cells were cultivated under constant stirring at 37 °C, 
5% CO2 and diluted with fresh medium every 24–48 h to a final culture volume of 1 l. Cells were treated with 1 µg/
ml doxycycline for 14 h to induce expression of TAP fusion proteins. All harvesting, centrifugation and purifica-
tion steps were performed at 4 °C or on ice. Cells were pelleted at 200 × g and washed once with ice-cold PBS. The 
cells were pelleted again, were resuspended in 20 ml lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 
10% (v/v) glycerol, 1% (v/v) Nonidet P-40, 1 mM DTT, 100 μM sodium vanadate, 1x protease inhibitor cock-
tail, ±10 µM olaparib) and lysed for 30 min under permanent agitation. Lysates were centrifuged at 15,000 × g 
for 20 min. The supernatant was incubated with 160 μl equilibrated IgG Sepharose for 1 h under permanent agi-
tation. Beads were pelleted at 500 × g for 3 min and washed three times with TEV buffer (50 mM Tris pH 7.5, 
150 mM NaCl, 0.5 mM EDTA, 1 mM DTT). The beads were pelleted and TEV cleavage was performed in 300 µl 
TEV buffer with 3 µl (30 U) of TEV protease for 3 h under permanent agitation. The bead supernatants were then 
transferred to a fresh tube. The IgG Sepharose pellet was resuspended in three volumes of CaM binding buffer 
(10 mM Tris pH 7.5, 150 mM NaCl, 0.2% (v/v) Nonidet P-40, 1 mM magnesium acetate, 2 mM CaCl2, 1 mM imi-
dazole, 10 mM β-mercaptoethanol) and pelleted again. The supernatant and the supernatant of the TEV cleavage 
were pooled for the subsequent CBP pulldown, which was performed after addition of 1/200 volume of 1 M 
CaCl2 to the supernatants with 50 µl equilibrated Calmodulin Sepharose for 90 min under permanent agitation. 
The beads were washed three times with CaM wash buffer (50 mM ammonium bicarbonate pH 8.0, 75 mM NaCl, 
1 mM magnesium acetate, 1 mM imidazole, 2 mM CaCl2). Residual buffer was removed carefully from the pellet 
and dry pellets were stored at −80 °C until mass spectrometry analysis.
Mass spectrometry analysis and data analysis. The dried pellets were processed for MS-analysis as 
described previously73. In brief, the dried beads from the TAP-purification were digested for 1 hour at room tem-
perature in 2 M urea, 50 mM Tris-HCl pH 7.5 and 5 μg/mL Trypsin, followed by two washes with 2 M urea, 50 mM 
Tris-HCl pH 7.5 and 1 mM DTT. The pooled supernatants were left to digest o/n at RT. After iodoacetamide mod-
ification and acidification of the samples, the peptides were desalted using homemade C18-tips and lyophilized. 
Peptides were analyzed on a Q-Exactive mass spectrometer connected to an Ultimate Ultra3000 chromatogra-
phy system incorporating an autosampler (both Thermo Scientific). Proteolytic peptides for each sample (5 μL) 
were applied to a home-made column (250-mm length, 75-μm inside diameter) (packed with 1.8 μm UChrom 
C18) and separated using a 40-min reverse-phase acetonitrile gradient [5–32% (vol/vol) acetonitrile] with a 
250-nL/min flow rate. The mass spectrometer was operated in positive ion mode with a capillary temperature 
of 220 °C and a 2200 V potential applied to the column. Analysis of +olaparib samples (two TAP-purifications): 
Peptides were loaded onto an Ultimate 3000 nanoLC system (Dionex/Thermo Scientific); trapped on a precolumn 
(Acclaim PepMap100, C18, 5 µm, 100 Å, 300 µm i.d. × 5 mm, Thermo Scientific) for 10 min and subsequently sep-
arated using an analytical column (Acclaim PepMap100, C18, 5 µm, 100 Å, 75 µm i.d. × 25 cm, Thermo Scientific) 
employing a 130 min gradient (0–10 min: 5% buffer B (buffer A: 0.1% FA; buffer B: 80% acetonitrile, 0.1% FA), 
10–105 min: 10–45% buffer B, 105–107 min: 45–100% buffer B; 107–113 100% buffer B; 113–130 min 5% buffer B). 
All samples were measured in duplicate on an Orbitrap Elite mass spectrometer (Thermo Scientific). MS settings: 
full scan spectra (Orbitrap) range: m/z 350 to m/z 1500, with a resolution of 120000 and an AGC setting of 5e5 
ions; data dependent mode; 20 s dynamic exclusion; top 10 precursor fragmentation in the ion trap with a colli-
sion energy of 35%.
Analysis of the raw data was performed using MaxQuant (version 1.5.1.2,74) with the built-in Andromeda 
search engine75. The spectra were searched against the human SwissProt database version 06/2015 (canonical 
and isoforms). The MaxQuant default settings (including mass tolerance) were used. Specific settings: Trypsin 
as the protease (two missed cleavages); Carbamidomethylation (Cys) as the fixed modification; Oxidation (Met), 
Phosphorylation (Ser, Thr, Tyr) and N-terminal protein acetylation as variable modifications: The false discovery 
rate was 0.01 on both peptide and protein level and the minimum peptide length was set to seven amino acids. 
Quantification was done using the label free quantitation algorithm from MaxQuant21,22.
Tables were created as follows: data was cleared of reversed hits, contaminants and “only identified by site”. 
Ratios were calculated from the LFQ values from TARG1-TAP vs. empty vector TAP. A student’s t-test was per-
formed with a minimum p-value of 0.01.
Co-immunoprecipitation (Co-IP). 1 × 106 HEK293 or HEK293T cells were seeded onto 10 cm dishes and 
transfected the next day with plasmid DNA as indicated (20 µg DNA in total) by calcium phosphate precipitation 
for 4–6 h. Cells were washed with HEPES buffer (142 mM NaCl, 10 mM HEPES, 6.7 mM KCl, pH 7.3) before cells 
were incubated in fresh medium for additional 48 h. All following harvesting and IP steps were performed at 4 °C 
or on ice. The cells were washed once with PBS, were harvested in 500 µl TAP lysis buffer (described above) and 
lysed for 30 min under permanent agitation. Lysates were cleared by centrifugation at 16.000 × g for 20 min. 30 µl 
TAP lysate were kept for input analyses and mixed with SDS sample buffer. Per IP sample 20 µl of anti-FLAG M2 
beads (suspension volume) were equilibrated in TAP lysis buffer before incubation with the remaining TAP lysate 
(~500 µl) for 30 min under constant rotation. Centrifugation of the beads was performed at 500 × g for 2 min. The 
beads were washed three times with 500 µl TAP lysis buffer. The buffer was removed from the beads completely 
and the beads were resuspended in 40 µl SDS sample buffer. Co-IP and input samples were incubated for 5 min at 
95 °C and analyzed by SDS-PAGE and Western blot.
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Purification of recombinant proteins. E. coli BL21 (DE3) were transformed with pGEX-4T1 or pDEST17 
plasmids encoding for GST-ALY, His-TARG1 proteins or His-CHIKV-nsP3-macro. Bacteria were cultured at 
37 °C in LB medium containing 0.4% glucose and protein expression was induced by addition of IPTG (1 mM) 
when an OD600 of 0.5–0.7 was reached. Purification of His-tagged proteins was performed by immobilized metal 
ion affinity chromatography (IMAC), all harvesting and purification steps were performed at 4 °C or on ice. 
Bacteria were pelleted and lysed in IMAC lysis buffer (100 mM HEPES, 500 mM NaCl, 10% glycerol, 10 mM 
imidazole, 0.5 mM TCEP, 1x protease inhibitor cocktail, 100 µg/ml lysozyme, pH 8.0) for 30 min. After soni-
cation and centrifugation, the lysate was incubated with equilibrated TALON metal affinity resin for 1 h. The 
beads were washed two times with PBS and once with IMAC wash buffer (20 mM HEPES, 500 mM NaCl, 10% 
glycerol, 10 mM imidazole, 0.5 mM TCEP, pH 7.5) and eluted with IMAC elution buffer (20 mM HEPES, 500 mM 
NaCl, 10% glycerol, 500 mM imidazole, 0.5 mM TCEP, pH 7.5). Glutathione affinity purification was performed 
as described previously76.
Thermal shift assay. The thermal shift assay was carried out in a final volume of 25 µl with 1 µg of recombi-
nant His-TARG1 proteins. First, a mastermix containing the assay buffer (100 mM HEPES, pH 7.5 and 150 mM 
NaCl), SYPRO orange (1:1,000 final dilution) and recombinant His-tagged protein (1 µg per reaction) was pre-
pared. 22.5 µl of the mixture were pipetted into one reaction tube and filled up with 2.5 µl of ligand solution or 
diluent as control. Each sample was measured in duplicates in a Rotorgene real-time PCR instrument (Corbett) 
using the 470 nm channel as the source for excitation and the 610 nm channel for detection with a gain of 7. A 
temperature scan (melt curve) from 25 °C to 95 °C was performed with temperature increasing by 1 °C/min. Data 
were analyzed according to25 using Boltzmann fitting.
Cell proliferation. For growth curve analysis, cells were seeded at 5 × 104 cells on 6 cm cell culture dishes in 
non-selective cell culture medium ±100 ng/ml doxycycline. HeLa OARD1−/− HA-TARG1 and HA-TARG1-G43E 
cells were pre-induced with doxycycline (100 ng/ml) to induce transgene expression before seeding. Fresh doxy-
cycline was added every 48–72 h throughout the analysis. Cells were trypsinized every 24 h and cell number was 
determined using the CASY® cell counter system (OMNI Life Science).
Live cell imaging. 5 × 104 U2OS cells were seeded onto high glass bottom 35 mm µ-dishes (ibidi) and trans-
fected with plasmids encoding for EGFP or EGFP-TARG1 fusion proteins and mCherry-tagged Histone H2B the 
next day. Treatment with DMSO or 10 µM olaparib was performed for 2 h before imaging. 48 h after transfection, 
the dishes were directly mounted onto a Zeiss LSM710 confocal laser scanning microscope and kept at 37 °C and 5% 
CO2. Images shown in Fig. 3a were acquired with a LD C-Apochromat 40x/1.1 W Korr M27 objective with a frame 
size of 512 × 512 px and a 1.5x digital zoom. EGFP fluorescence was excited with the 488 nm line of an Argon laser 
(25 mW, 2% output) and detected from 493 nm to 586 nm with a main beam splitter filter MBS 488. mCherry fluo-
rescence was excited with a 561 nm DPSS laser (20 mW, 2% output) and detected from 578 nm to 696 nm with a MBS 
458/561 filter. Imaging was performed on a 2.2 µm section, corresponding to 2.17 airy units (AU) in the EGFP track 
and 1.83 AU in the mCherry track. Images shown in Figs 3b,c and 5 were acquired with a C-Apochromat 63x/1.20 W 
Korr objective with a frame size of 1024 × 1024 px. Settings for excitation and detection were as described above. For 
each channel the pinhole diameter was set to 1 AU, corresponding to a 0.9 µm section in the EGFP track and a 1.1 µm 
section in the mCherry track. The pixel dwell time was 6.3 µs (Fig. 3b) or 3.15 µs (Figs 3c and 5). Time series were 
performed at 20 cycles with 1 min interval using Definite Focus for focus stabilization.
Intensity values were extracted from unprocessed images using the Zen2012 software (Fig. 3a) or ImageJ 1.47 
(Fig. 5, Supplementary Fig. S7)77. Normalized intensities as depicted in Fig. 5b and d were measured using the 
ImageJ Time Series Analyzer V3 plugin. Intensities of circular ROIs covering the nucleolar areas and of three cir-
cular ROIs placed randomly throughout the nucleoplasmic area were measured for each time point. To account 
for changes in focus over time, the mean nucleolar EGFP intensity was normalized to the mean nuclear EGFP 
intensity at each time point for each cell analyzed. Nucleolar EGFP intensities were normalized to the nucleolar 
EGFP intensity 1 min after treatment.
Only linear adjustments of the histogram range of single channels were performed to increase the image 
contrast. Adjustments were performed on an entire image and were equally applied to all images belonging to a 
single experiment.
Fluorescence loss in photo-bleaching (FLIP). Cell seeding and treatments were performed as described 
for live cell imaging. FLIP experiments were performed with a Zeiss LSM710 confocal laser scanning micro-
scope using a C-Apochromat 63x/1.2 W Korr objective. The 488 nm line of an Argon laser (25 mW, 1% output 
for imaging scans) was used for excitation of EGFP. EGFP fluorescence was detected from 493 nm to 574 nm. 
mCherry fluorescence was acquired to localize nuclei and nucleoli. mCherry was excited with a 561 nm DPSS 
laser (20 mW, 1% output for imaging scans) and fluorescence detected from 578 nm to 696 nm. A MBS 488/561 
filter was applied for detection of EGFP and mCherry fluorescence. Imaging and bleaching were performed on 
a 2 µm section, corresponding to 2.39 AU in the EGFP track and 2 AU in the mCherry track. The frame size was 
set to 512 × 512 px. The pixel dwell time was 1.27 µs during imaging. Initial photo-bleaching of a circular ROI 
(∅2.8 µm, width and height of 11 px) was performed after 5 imaging scans using the 488 nm laser at 100% inten-
sity with 100 iterations applying a different scan speed (pixel dwell time of 25.21 µs) and the zoom bleach option. 
Bleaching was repeated after every imaging scan. Nuclear photo-bleaching was performed for 60 s, after which 
imaging was continued without photo-bleaching for additional 30 s. The average fluorescence intensities in each 
of the defined ROIs were measured during imaging using the Zen2012 software. The ROI area was kept constant 
for every sample and cells of similar size were chosen. At least 7 data sets were analyzed per sample. Fluorescence 
intensities in each ROI were normalized to the mean fluorescence intensity in the same ROI before bleaching.
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RNA binding assay. RNA EMSAs were performed as described previously41. Briefly, pcDNA3.1-based 
Pentaprobe plasmids were linearized by ApaI followed by a Klenow-fill in of 3′ overhangs. 1 µg of purified, lin-
earized plasmid DNA was in vitro transcribed using the T7 RiboMAX™ Large Scale RNA Production System 
(Promega) in the presence of α-32P-UTP. The in vitro transcription reaction was separated on denaturing 
urea-TBE polyacrylamide gels. The gel slice containing the labeled RNA Pentaprobe fragment was crushed and 
soaked in H2O over night. Samples were centrifuged and the supernatant containing the labeled RNA was trans-
ferred to a new reaction tube. The soaking step was repeated for 2 h. Supernatants from both soaking steps were 
combined and the RNA was ethanol-precipitated over night at −20 °C. The precipitation reaction was centrifuged 
for 30 min at 4 °C at 13,000 × g. The ethanol was removed carefully and the RNA pellet incubated at 37 °C until 
residual ethanol was evaporated completely. The RNA pellet was resuspended in 100–150 µl TBE buffer and incu-
bated at 37 °C for 5–10 min. Probes were stored at −20 °C until use and, directly before use, were heated for 45 s at 
95 °C and put straight on ice. RNA binding reactions were carried out in a 30 µl volume with 1 µl of labeled RNA 
and 0–20 pmol of recombinant protein in gel shift buffer (10 mM MOPS pH 7.0, 50 mM KCl, 5 mM MgCl2, 1 mM 
DTT, 10% glycerol) for 30 min at 4 °C. For antibody supershift experiments, 500 ng of an anti-TARG1 antibody 
(polyclonal, Eurogentec) were added prior to addition of the labeled RNA. The binding reactions were loaded 
onto 7% acrylamide/bisacrylamide (19:1) gels and electrophoresed in TB buffer (45 mM Tris, 45 mM boric acid) 
at 10 mA at 4 °C for 2–3 h. Gels were dried and analyzed by auto-radiography.
Preparation of whole cell lysates for western blot analyses. For the preparation of whole cell lysates, 
cells were harvested in RIPA buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% (v/v) Nonidet P-40, 1% (v/v) deoxy-
cholate, 0.1% SDS, 1x protease inhibitor cocktail) and sonicated. Cell lysates were centrifuged at 16,000 × g, 4 °C 
for 20 min. The supernatant was transferred to a fresh reaction tube, mixed with SDS sample buffer, heated for 
5 min at 95 °C and analyzed by SDS-PAGE/Western blotting.
Data availability. The mass spectrometry proteomics data (raw MS data), MaxQuant output txt files and 
the corresponding fasta file have been deposited to the ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository78 with the dataset identifier PXD008748.
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